Critical reviews in oncology/hematology
Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients.
Zuer He, Zijia Luo, Peilin Dai, Xiaoli Wang, Jiqiao Yang
Published: 202610.1016/j.critrevonc.2026.105153
Abstract
Antibody-drug conjugates (ADCs) constitute an innovative category of anti-tumor therapeutics that selectively deliver cytotoxins to tumor cells, improving efficacy and reducing toxicity in comparison to systemic therapy. TROP2 serves as a significant…
Preview only. Read the full abstract at the source